Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Thermocore Medical Systems

This article was originally published in The Gray Sheet

Executive Summary

Venture capital arm of the Bank of Cyprus and a group of private investors provides "several" million dollars in funding for preclinical development of a thermography catheter to identify previously undetectable and high-risk areas of diseased coronary arteries. Working in cooperation with consulting firm Arthur D. Little, Thermocore will incorporate an array of sensors to map the interior of arteries on the basis of temperature variations. "Clinical data generated by an early version of such a device showed greater thermal variations in patients with unstable angina and acute myocardial infarction than in patients with normal coronary arteries," Thermocore explains in a release. The device, which would serve as a complement to angiograms, is expected to enter European trials within six to eight months and begin U.S. trials in the second half of 2002

You may also be interested in...



Pandemic-Related Price-Gouging Would Be False, Misleading Advertising Under House, Senate Bills

House and Senate Democrats sponsor legislation to authorize FTC enforcement against sales of "consumer goods and services at an unconscionably excessive price during the" COVID-19 pandemic. "It’s outrageous that some companies and individuals are taking advantage of consumers by price-gouging," says Energy and Commerce Committee Chairman Frank Pallone.

COVID-19 Trial Changes Are “Propulsive Force” For Digital Adoption

Robert Califf, a former FDA commissioner turned Verily Life Sciences exec, is just one of the voice predicting a long-term impact on clinical trial processes from the COVID-19 outbreak.

Digital Doublespeak: The Language Barrier When Tech Companies Meet Regulators

A US National Academies meeting on digital health technology showcased the communication gap between regulators and tech developers when it comes to important concepts like “digital biomarkers.”

UsernamePublicRestriction

Register

MT014697

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel